Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Neurocrine Biosciences / Equity Bottom-Up

<ul><li>In the third quarter of 2025, Neurocrine Biosciences reported robust financial and operational performance.</li><li>The period was marked by $790 million in net product sales, a 28% year-over-year increase, driven by their flagship drugs INGREZZA and CRENESSITY.</li><li>INGREZZA, used for treating tardive dyskinesia and Huntington’s chorea, saw continued growth attributed to recent expansions of the sales force and improved patient access, resulting in record new patient starts and prescriptions.</li></ul>

In the third quarter of 2025, Neurocrine Biosciences reported robust financial and operational performance.The period was marked by $790 million in net product sales, a 28% year-over-year increase, driven by their flagship drugs INGREZZA and CRENESSITY.INGREZZA, used for treating tardive dyskinesia and Huntington’s chorea, saw continued growth attributed to recent expansions of the sales force and improved patient access, resulting in record new patient starts and prescriptions.

Neurocrine Biosciences Doubles Down on CRENESSITY – Can This Strategy Dominate the CAH Market?

<ul><li>Neurocrine Biosciences reported an impressive second quarter of 2025, reflecting both strong financial performance and promising strategic developments.</li><li>The company generated $682 million in net product sales, marking a 17% increase year-over-year.</li><li>This growth was driven by its key products, INGREZZA and CRENESSITY, which have shown solid market penetration.</li></ul>

Neurocrine Biosciences reported an impressive second quarter of 2025, reflecting both strong financial performance and promising strategic developments.The company generated $682 million in net product sales, marking a 17% increase year-over-year.This growth was driven by its key products, INGREZZA and CRENESSITY, which have shown solid market penetration.

Neurocrine Biosciences Just Launched CRENESSITY—What’s Fueling Its Rapid Uptake Among Endocrinologists?

<ul><li>Neurocrine Biosciences, in its first quarter of 2025 results communication, highlighted noteworthy progress in both its product sales and promising initial uptake of new therapeutic offerings.</li><li>Despite external market volatility, the company's focus on execution was evident in the strong performance of its established brands and new product launches.</li><li>On the positive side, the first quarter showcased record new patient starts for INGREZZA, a crucial treatment in their portfolio, alongside encouraging initial results from the CRENESSITY launch.</li></ul>

Neurocrine Biosciences, in its first quarter of 2025 results communication, highlighted noteworthy progress in both its product sales and promising initial uptake of new therapeutic offerings.Despite external market volatility, the company's focus on execution was evident in the strong performance of its established brands and new product launches.On the positive side, the first quarter showcased record new patient starts for INGREZZA, a crucial treatment in their portfolio, alongside encouraging initial results from the CRENESSITY launch.

Neurocrine Biosciences: Adoption of CRENESSITY For A Substantial Opportunity For Growth In The Endocrinology Segment!

<ul><li>Neurocrine Biosciences' recent earnings provides a comprehensive overview of its financial performance, strategic initiatives, and growth prospects through the lens of both successes and areas of caution.</li><li>The company continues to demonstrate solid performance with key products while also facing challenges in a competitive biopharmaceutical landscape.</li><li>Positives from the call highlight the standout performance of INGREZZA, Neurocrine's treatment for tardive dyskinesia, which has achieved record growth.</li></ul>

Neurocrine Biosciences' recent earnings provides a comprehensive overview of its financial performance, strategic initiatives, and growth prospects through the lens of both successes and areas of caution.The company continues to demonstrate solid performance with key products while also facing challenges in a competitive biopharmaceutical landscape.Positives from the call highlight the standout performance of INGREZZA, Neurocrine's treatment for tardive dyskinesia, which has achieved record growth.

Neurocrine Biosciences: The CRENESSITY Launch & Expansion As A Significant Growth Opportunity!

<ul><li>Neurocrine Biosciences has presented its third-quarter 2024 results, highlighting both achievements and ongoing strategic initiatives.</li><li>Under the new leadership of CEO Kyle Gano, the company is focusing on strengthening its position as a leading neuroscience organization.</li><li>Its revenue growth has been particularly driven by the performance of its drug INGREZZA, with an impressive $613 million in sales this quarter, translating to 25% year-over-year growth.</li></ul>

Neurocrine Biosciences has presented its third-quarter 2024 results, highlighting both achievements and ongoing strategic initiatives.Under the new leadership of CEO Kyle Gano, the company is focusing on strengthening its position as a leading neuroscience organization.Its revenue growth has been particularly driven by the performance of its drug INGREZZA, with an impressive $613 million in sales this quarter, translating to 25% year-over-year growth.

Neurocrine Biosciences: Commercial Expansion & Market Penetration Underpinning Our ‘Outperform’ Rating! - Major Drivers

United States

Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders.  The Company is developing therapeutic interventions for anxiety, depression, Alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Neurocrine Biosciences (NBIX US)

Neurocrine Biosciences Doubles Down on CRENESSITY – Can This Strategy Dominate the CAH Market?

In the third quarter of 2025, Neurocrine Biosciences reported robust financial and operational performance. The period was marked by $790 million...

Baptista Research

Neurocrine Biosciences Just Launched CRENESSITY—What’s Fueling Its Rapid Uptake Among Endocrinologists?

Neurocrine Biosciences reported an impressive second quarter of 2025, reflecting both strong financial performance and promising strategic...

Baptista Research

Neurocrine Biosciences: Adoption of CRENESSITY For A Substantial Opportunity For Growth In The Endocrinology Segment!

Neurocrine Biosciences, in its first quarter of 2025 results communication, highlighted noteworthy progress in both its product sales and...

Baptista Research

Neurocrine Biosciences: The CRENESSITY Launch & Expansion As A Significant Growth Opportunity!

Neurocrine Biosciences' recent earnings provides a comprehensive overview of its financial performance, strategic initiatives, and growth...

Baptista Research

Neurocrine Biosciences: Commercial Expansion & Market Penetration Underpinning Our ‘Outperform’ Rating! - Major Drivers

Neurocrine Biosciences has presented its third-quarter 2024 results, highlighting both achievements and ongoing strategic initiatives. Under the...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)